Chiesi Ventures, Inc. 3
3 · Kezar Life Sciences, Inc. · Filed Jun 25, 2018
Insider Transaction Report
Form 3
Chiesi Ventures, Inc.
10% Owner
Holdings
- (indirect: See footnote)
Series B Preferred Stock, par value $0.001 per share
From: 2017-06-26→ Common Stock, par value $0.001 per share (314,819 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock, par value $0.001 per share (the "Series B Stock") is convertible into Common Stock, $0.001 par value per share (the "Common Stock") of Kezar Life Sciences, Inc. (the "Company") on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-5.62 reverse stock split that was effected by the Company on June 8, 2018.
- [F2]These shares are held of record by Chiesi Ventures, LP ("Chiesi Ventures"). Chiesi Ventures, Inc. ("Chiesi") is the general partner of Chiesi Ventures, and Mr. Giacomo Chiesi is President of, and may be deemed to have control of, Chiesi. By virtue of their respectively relationships with Chiesi Ventures, each of Chiesi and Mr. Chiesi may be deemed to indirectly beneficially own the shares of which Chiesi Ventures is the record owner. Each of Chiesi and Mr. Chiesi disclaims beneficial ownership of the shares reported herein, except to the extent of its or his respective pecuniary interests therein. This report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.